Actinium Pharmaceuticals (ATNM) Competitors $1.78 -0.11 (-5.56%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ATNM vs. KOD, CGC, ACRS, RZLT, FDMT, ALMS, MDWD, GNFT, ACRV, and FULCShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Kodiak Sciences (KOD), Canopy Growth (CGC), Aclaris Therapeutics (ACRS), Rezolute (RZLT), 4D Molecular Therapeutics (FDMT), Alumis (ALMS), MediWound (MDWD), Genfit (GNFT), Acrivon Therapeutics (ACRV), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Kodiak Sciences Canopy Growth Aclaris Therapeutics Rezolute 4D Molecular Therapeutics Alumis MediWound Genfit Acrivon Therapeutics Fulcrum Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Is ATNM or KOD more profitable? Kodiak Sciences' return on equity of -84.52% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Kodiak Sciences N/A -84.52%-45.40% Which has more risk & volatility, ATNM or KOD? Actinium Pharmaceuticals has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Does the media refer more to ATNM or KOD? In the previous week, Actinium Pharmaceuticals and Actinium Pharmaceuticals both had 9 articles in the media. Kodiak Sciences' average media sentiment score of 0.73 beat Actinium Pharmaceuticals' score of 0.14 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, ATNM or KOD? Actinium Pharmaceuticals has higher revenue and earnings than Kodiak Sciences. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$81K727.91-$48.82M-$1.39-1.36Kodiak SciencesN/AN/A-$260.49M-$3.65-0.84 Does the MarketBeat Community favor ATNM or KOD? Kodiak Sciences received 11 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. However, 50.00% of users gave Actinium Pharmaceuticals an outperform vote while only 27.54% of users gave Kodiak Sciences an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes850.00% Underperform Votes850.00% Kodiak SciencesOutperform Votes1927.54% Underperform Votes5072.46% Do institutionals & insiders have more ownership in ATNM or KOD? 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 45.3% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ATNM or KOD? Actinium Pharmaceuticals presently has a consensus price target of $7.40, suggesting a potential upside of 291.53%. Kodiak Sciences has a consensus price target of $8.00, suggesting a potential upside of 161.44%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Kodiak Sciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryKodiak Sciences beats Actinium Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Remove Ads Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$58.96M$6.92B$5.65B$19.62BDividend YieldN/A2.72%4.57%3.75%P/E Ratio-1.367.2023.1733.60Price / Sales727.91226.01385.1927.47Price / CashN/A65.6738.1617.54Price / Book1.446.476.944.60Net Income-$48.82M$141.90M$3.20B$1.02B7 Day Performance21.94%-3.20%-2.29%0.37%1 Month Performance64.35%-5.64%2.88%-2.45%1 Year Performance-75.86%-7.47%10.82%5.03% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.7849 of 5 stars$1.79-5.6%$7.40+314.6%N/A$55.78M$81,000.00-1.2930Analyst ForecastAnalyst RevisionNews CoverageGap UpKODKodiak Sciences4.0414 of 5 stars$3.52+7.3%$8.00+127.3%-58.9%$185.24MN/A-0.9690Earnings ReportUpcoming EarningsNews CoverageGap DownCGCCanopy Growth2.4277 of 5 stars$1.16+4.5%$2.00+72.4%-89.0%$183.99M$276.75M-0.313,150Positive NewsACRSAclaris Therapeutics2.1549 of 5 stars$1.70+6.3%$11.67+586.3%+28.6%$183.46M$18.72M-3.27100Short Interest ↑RZLTRezolute2.5853 of 5 stars$3.03-0.7%$24.38+704.5%+30.4%$183.42MN/A-2.4840News CoverageFDMT4D Molecular Therapeutics2.8367 of 5 stars$3.93+0.3%$30.63+679.3%-90.1%$181.97M$37,000.00-1.38120ALMSAlumisN/A$3.78+0.8%$26.00+587.8%N/A$178.50MN/A0.00N/AAnalyst ForecastAnalyst RevisionMDWDMediWound1.673 of 5 stars$16.45+1.1%$31.33+90.5%+12.5%$177.55M$20.22M-5.6780GNFTGenfit2.1213 of 5 stars$3.53-2.8%$13.00+268.3%+0.9%$176.49M$76.06M0.00120Upcoming EarningsGap UpACRVAcrivon Therapeutics2.2655 of 5 stars$5.61+4.7%$23.67+321.9%-61.0%$174.67MN/A-2.0858Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageFULCFulcrum Therapeutics1.743 of 5 stars$3.21+1.9%$8.63+168.7%-67.3%$173.27M$80M-10.35100News CoveragePositive News Remove Ads Related Companies and Tools Related Companies Kodiak Sciences Alternatives Canopy Growth Alternatives Aclaris Therapeutics Alternatives Rezolute Alternatives 4D Molecular Therapeutics Alternatives Alumis Alternatives MediWound Alternatives Genfit Alternatives Acrivon Therapeutics Alternatives Fulcrum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNM Stock Free ATNM Stock Alerts